MX2021003773A - Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. - Google Patents
Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.Info
- Publication number
- MX2021003773A MX2021003773A MX2021003773A MX2021003773A MX2021003773A MX 2021003773 A MX2021003773 A MX 2021003773A MX 2021003773 A MX2021003773 A MX 2021003773A MX 2021003773 A MX2021003773 A MX 2021003773A MX 2021003773 A MX2021003773 A MX 2021003773A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- therapeutic agents
- related methods
- otic therapeutic
- methods
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739933P | 2018-10-02 | 2018-10-02 | |
| PCT/US2019/054235 WO2020072601A1 (en) | 2018-10-02 | 2019-10-02 | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003773A true MX2021003773A (es) | 2021-07-16 |
Family
ID=68296763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003773A MX2021003773A (es) | 2018-10-02 | 2019-10-02 | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220192984A1 (https=) |
| EP (1) | EP3860562A1 (https=) |
| JP (1) | JP2022504265A (https=) |
| KR (1) | KR20210084484A (https=) |
| CN (1) | CN113164381A (https=) |
| BR (1) | BR112021006092A2 (https=) |
| CA (1) | CA3114113A1 (https=) |
| MX (1) | MX2021003773A (https=) |
| TW (1) | TW202034900A (https=) |
| WO (2) | WO2020072602A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| CN113195707A (zh) * | 2018-08-17 | 2021-07-30 | 频率治疗公司 | 用于通过上调jag-1来生成毛细胞的组合物和方法 |
| KR20220007050A (ko) * | 2019-04-08 | 2022-01-18 | 프리퀀시 테라퓨틱스, 인크. | 난청을 치료하기 위한 chir99021과 발프로산의 조합 |
| CN114085803B (zh) * | 2020-08-24 | 2024-04-26 | 北京大学 | 建立具有再生特性的类器官培养体系 |
| CA3195622A1 (en) * | 2020-10-14 | 2022-04-21 | Ear Science Institute Australia Incorporated | Methods for generating inner ear hair cells |
| WO2022192079A1 (en) * | 2021-03-08 | 2022-09-15 | The Regents Of The University Of California | Compounds for protection of noise-induced hearing-loss |
| EP4629989A2 (en) * | 2022-12-07 | 2025-10-15 | Freedom Biosciences, Inc. | Treatment or prevention of depressive disorders through combination therapy |
| CN120053473B (zh) * | 2025-04-25 | 2025-07-18 | 山东大学 | 赖氨酸甲基转移酶dot1l抑制剂在制备治疗肝脏缺血再灌注损伤药物中的应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US447475A (en) | 1891-03-03 | pomerof | ||
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US5346703A (en) | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| WO2000007603A2 (en) | 1998-08-04 | 2000-02-17 | Madash Llp | End modified thermal responsive hydrogels |
| US6761824B2 (en) | 2000-08-17 | 2004-07-13 | Reeve Lorraine E | Process for the fractionation of polymers |
| WO2009009737A1 (en) * | 2007-07-12 | 2009-01-15 | Neurosci, Inc. | Sustained release formulation of active pharmaceuticals in a lipid based sustained release |
| EP2732819B1 (en) | 2008-02-07 | 2019-10-16 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
| EP2854809B1 (en) | 2012-06-01 | 2017-12-06 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI) | Inhibitors of the notch signalling pathway and secretion for use in medicine |
| CA2883896C (en) | 2012-09-07 | 2023-03-07 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2014047391A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
| EP2897960B1 (en) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
| EP2897947B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
| EP2897954B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| US9572815B2 (en) | 2013-03-15 | 2017-02-21 | St. Jude Children's Research Hospital | Methods and compositions of p27KIP1 transcriptional modulators |
| CN103169649A (zh) * | 2013-04-11 | 2013-06-26 | 中国人民解放军总医院 | 温度和离子双重敏感型原位凝胶鼻腔给药系统 |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| WO2016037016A1 (en) * | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| CN107075471A (zh) | 2014-10-08 | 2017-08-18 | 新加坡科技研究局 | 将干细胞分化为肝细胞谱系的方法 |
| TWI625332B (zh) | 2015-07-07 | 2018-06-01 | 美國禮來大藥廠 | 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物 |
| KR102723605B1 (ko) | 2015-12-22 | 2024-10-29 | 바스프 에스이 | 폴리에테르 블록 공중합체의 정제 방법 |
| US10201540B2 (en) * | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) * | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| JP7012715B2 (ja) | 2016-06-27 | 2022-01-28 | エフ．ホフマン－ラ ロシュ アーゲー | γ－セクレターゼモジュレーターとしてのトリアゾロピリジン |
| EP3481829B1 (en) | 2016-07-08 | 2021-04-07 | H. Hoffnabb-La Roche Ag | Fused pyrimidine derivatives |
| EP3484884B1 (en) | 2016-07-14 | 2021-01-27 | Hoffmann-La Roche AG | Fused pyrimidine derivatives |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| EP3523304B1 (en) | 2016-10-04 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bicyclic heteroaryl derivatives |
| TWI757360B (zh) | 2016-11-08 | 2022-03-11 | 瑞士商赫孚孟拉羅股份公司 | 苯氧基三唑 |
| MX390370B (es) | 2016-12-16 | 2025-03-20 | Pipeline Therapeutics Inc | Metodos para tratar la sinaptopatia coclear |
| CA3047730A1 (en) | 2016-12-20 | 2018-06-28 | Oligomerix, Inc. | Quinazolinones that inhibit the formation of tau oligomers and their method of use |
| CA3047729A1 (en) | 2016-12-20 | 2018-06-28 | Oligomerix, Inc. | Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use |
| US10383881B2 (en) | 2016-12-30 | 2019-08-20 | Frequency Therapeutics, Inc. | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same |
| US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
| WO2018172997A1 (en) | 2017-03-24 | 2018-09-27 | Novartis Ag | Isoxazole carboxamide compounds and uses thereof |
-
2019
- 2019-10-02 TW TW108135698A patent/TW202034900A/zh unknown
- 2019-10-02 MX MX2021003773A patent/MX2021003773A/es unknown
- 2019-10-02 US US17/282,069 patent/US20220192984A1/en not_active Abandoned
- 2019-10-02 CN CN201980079535.3A patent/CN113164381A/zh active Pending
- 2019-10-02 JP JP2021518610A patent/JP2022504265A/ja not_active Withdrawn
- 2019-10-02 WO PCT/US2019/054236 patent/WO2020072602A1/en not_active Ceased
- 2019-10-02 CA CA3114113A patent/CA3114113A1/en active Pending
- 2019-10-02 EP EP19791035.9A patent/EP3860562A1/en not_active Withdrawn
- 2019-10-02 KR KR1020217013189A patent/KR20210084484A/ko not_active Withdrawn
- 2019-10-02 BR BR112021006092-8A patent/BR112021006092A2/pt not_active Application Discontinuation
- 2019-10-02 WO PCT/US2019/054235 patent/WO2020072601A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3114113A1 (en) | 2020-04-09 |
| CN113164381A (zh) | 2021-07-23 |
| TW202034900A (zh) | 2020-10-01 |
| BR112021006092A2 (pt) | 2021-07-20 |
| US20220192984A1 (en) | 2022-06-23 |
| KR20210084484A (ko) | 2021-07-07 |
| WO2020072601A1 (en) | 2020-04-09 |
| WO2020072602A1 (en) | 2020-04-09 |
| EP3860562A1 (en) | 2021-08-11 |
| JP2022504265A (ja) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
| MX2022007140A (es) | Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3). | |
| MY202018A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| SG10201902429PA (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MY207121A (en) | Anti-ror antibody constructs | |
| PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
| PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
| PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| SA523440384B1 (ar) | مركبات الفوسفوليبيدات واستخداماتها | |
| PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| PH12022551105A1 (en) | Tyk2 pseudokinase ligands | |
| MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| WO2019200314A3 (en) | Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof | |
| MY209035A (en) | Tricyclic compounds and their use | |
| MX2025013942A (es) | Anticuerpos contra mucina 16 y metodos de uso de los mismos | |
| WO2017098051A3 (en) | Combined preparations of pkm2 modulators and hmgb1 | |
| SA520420261B1 (ar) | تركيبات إرنوماب واستخداماتها | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. | |
| WO2018085551A3 (en) | Formulations of pegylated arginine deiminase | |
| WO2018119312A8 (en) | Methods and formulations for reducing reconstitution time of lyophilized polypeptides |